G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line

Journal of Orthopaedic Research

Volumn 24, Issue 3, 2006, Pages 474-480

  Joyner, David E ^a   Albritton, Karen H ^a,b   Bastar, Jeffrey D ^a   Randall, R Lor ^a  

^a UNIVERSITY OF UTAH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Bcl 2 antisense; Doxorubicin; Synovial sarcoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2; PROTEIN BCL XL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SYNOVIAL SARCOMA; WESTERN BLOTTING; CONNECTIVE TISSUE TUMOR; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS;

EID: 33645736984     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20087     Document Type: Article

References (12)

1. Lopez JM, Hannisdal E, Bjerkehagen B, et al. 1998. Synovial sarcoma: evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Anal Cell Pathol 16:45-62.
2. Schwarzbach MH, Eisold S, Burguete T, et al. 2002. Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol 20: 1211-1218.
3. Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. 2002. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 26:1434-1440.
4. Kohler T, Wurl P, Meye A, et al. 2002. High Bad and Bcl-xL gene expression and combined Bad, Bcl-xL Bax, and Bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients. Anticancer Res 22:1553-1559.
5. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. 2000. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891-2902.
6. Joyner D, Wade M, Szabo A, et al. 2005. Discriminate gene lists derived from cDNA microarray profiles of limited samples permit distinguishing mesenchymal neoplasia ex vivo. J Cancer Res Clin Oncol 131:137-146.
7. Nishio J, Iwasaki H, Ishiguro M, et al. 2002. Establishment of a new human synovial sarcoma cell line, FU-SY-1, that expresses c-Met receptor and its ligand hepatocyte growth factor. Int J Oncol 21:7-23.
8. Mancuso T, Mezzelani A, Riva C, et al. 2000. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 80:805-813.
9. Huigsloot M, Tijdens IB, Mulder GJ, et al. 2002. Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. J Biol Chem 277:35869-35879.
10. Perreard L, Robison JE, Bastein RRL, et al. 2003. Breast cancer profiling using real time RT-PCR techniques. J Clin Ligand Assay 26:191-195.
11. Ferrari A, Gronchi A, Casanova M, et al. 2004. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101:627-634.
12. Zalupski MM, Rankin C, Ryan JR, et al. 2004. Adjuvant therapy of osteosarcoma - a phase II trial. Cancer 100:818-825.